Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows It Produced Robust Antibodies and T Cells Against SARS-CoV-2

LOS ANGELES & ATLANTA--(BUSINESS WIRE)--COVID-19 investigational vaccine developed by City of Hope produced neutralizing antibodies and T cells with no major side effects in Phase 1 trial.

Click to view original post